Security
CLGN · CollPlant Biotechnologies Ltd
CLGNNASDAQCommon stockCurrentCIK 1631487Updated Sep 26, 2026
Name history
CollPlant Biotechnologies Ltd. · through Jun 20, 2019CollPlant Holdings Ltd. · through Jun 6, 2019
CLGN price & chart
Loading TradingView…
NASDAQ:CLGN on TradingView ↗About the company
We are a regenerative and aesthetic medicine company focused on medical aesthetics and 3D bioprinting of tissues and organs. Our products are based on our recombinant human collagen (rhCollagen) that is produced in genetically engineered tobacco plants using our proprietary technology. These products address indications for the diverse fields of tissue repair and aesthetics, and are ushering in a new era in regenerative and aesthetic medicine.
In the news
COLLPLANT BIOTECHNOLOGIES ANNOUNCES DATE FOR 2025 THIRD QUARTER FINANCIAL RESULTS News provided by CollPlant Nov 18, 2025, 07:00 ET Share this article Share to X Share this article Share to X REHOVOT, Israel , Nov. 18, 2025 /PRNewswire/ -- CollPlant Biotechnologies (Nasdaq: CLGN ), a regenerative an ↗
Seeking Alpha
CollPlant regains Nasdaq compliance ↗
CollPlant Biotechnologies Ltd. (CLGN) Discusses Acquisition of Lightsolver and Strategic Entry Into High-Performance Photonic Computing - Slideshow ↗
CollPlant Biotechnologies Ltd. (CLGN) Discusses Acquisition of Lightsolver and Strategic Entry Into High-Performance Photonic Computing Transcript ↗
Recent filings
Show 5 more recent filings
Financials
FY 2025 · USDSource
Source
Source
Source
Source
Source
balance sheet · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| ASSETS | ||||
| AssetsUSD | 10,785,000Source | 18,710,000Source | 34,126,000Source | 37,768,000Source |
| Property, Plant and Equipment, NetUSD | 1,463,000Source | 2,290,000Source | 2,789,000Source | 2,966,000Source |
| Intangible Assets, Net (Excluding Goodwill)USD | 73,000Source | 131,000Source | 188,000Source | 245,000Source |
| Current assets: | ||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 5,591,000Source | 11,909,000Source | 26,674,000Source | 29,653,000Source |
| Accounts Receivable, after Allowance for Credit Loss, CurrentUSD | 1,000Source | 150,000Source | — | 9,000Source |
| Inventory, NetUSD | 573,000Source | 440,000Source | 714,000Source | 1,430,000Source |
| Assets, CurrentUSD | 6,747,000Source | 13,180,000Source | 28,022,000Source | 31,658,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 223,000Source | 433,000Source | 393,000Source | 543,000Source |
| Operating Lease, Right-of-Use AssetUSD | 2,426,000Source | 2,991,000Source | 3,070,000Source | 2,711,000Source |
| LIABILITIES AND EQUITY | ||||
| LiabilitiesUSD | 4,704,000Source | 5,245,000Source | 5,786,000Source | 5,487,000Source |
| Stockholders’ equity: | ||||
| Common Stock, Value, IssuedUSD | 5,492,000Source | 4,983,000Source | 4,982,000Source | 4,873,000Source |
| Retained Earnings (Accumulated Deficit)USD | -124,839,000Source | -113,350,000Source | -96,741,000Source | -89,722,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | -969,000Source | -969,000Source | -969,000Source | — |
| Stockholders' Equity Attributable to ParentUSD | 6,081,000Source | 13,465,000Source | 28,340,000Source | 32,281,000Source |
| Additional Paid in Capital, Common StockUSD | 126,397,000Source | 122,801,000Source | 121,068,000Source | — |
| Liabilities and EquityUSD | 10,785,000Source | 18,710,000Source | 34,126,000Source | 37,768,000Source |
| Current liabilities: | ||||
| Liabilities, CurrentUSD | 2,672,000Source | 2,970,000Source | 3,251,000Source | 3,105,000Source |
| Operating Lease, Liability, CurrentUSD | 814,000Source | 806,000Source | 624,000Source | 529,000Source |
| Operating Lease, Liability, NoncurrentUSD | 2,032,000Source | 2,275,000Source | 2,535,000Source | 2,382,000Source |
cash flow · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | — | — | — | -16,925,000Source |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||
| Depreciation, Depletion and AmortizationUSD | 912,000Source | 1,038,000Source | 1,102,000Source | — |
| Share-based Payment Arrangement, Noncash ExpenseUSD | 999,000Source | 1,719,000Source | 1,937,000Source | — |
| Changes in operating assets and liabilities: | ||||
| Increase (Decrease) in Accounts ReceivableUSD | -149,000Source | 150,000Source | -9,000Source | -261,000Source |
| Increase (Decrease) in InventoriesUSD | 129,000Source | -280,000Source | -749,000Source | 312,000Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | -9,419,000Source | -14,093,000Source | -2,763,000Source | -13,698,000Source |
| Cash flows from investing activities: | ||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | -27,000Source | -539,000Source | -1,156,000Source | 28,922,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | 28,000Source | 483,000Source | 954,000Source | 1,274,000Source |
| Cash flows from financing activities: | ||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | 3,102,000Source | 9,000Source | 1,108,000Source | 1,874,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | -6,318,000Source | -14,765,000Source | -3,190,000Source | 16,490,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | 5,591,000Source | 11,909,000Source | 26,674,000Source | — |
| Supplemental disclosure of cash flow information: | ||||
| Income Taxes Paid, NetUSD | 16,000Source | 62,000Source | 8,000Source | — |
| Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | 26,000Source | -142,000Source | -379,000Source | -608,000Source |
| Additional Financial Items | ||||
| Share-based Payment Arrangement, ExpenseUSD | 1,003,000Source | 1,719,000Source | 1,937,000Source | — |
| AssetAcquisitionContingentConsiderationLiabilityUSD | 14,000,000Source | 14,000,000Source | 14,000,000Source | 14,000,000Source |
| DepreciationUSD | 854,000Source | 981,000Source | 1,045,000Source | 1,076,000Source |
| Gain (Loss) on Sale of InvestmentsUSD | — | — | — | 87,000Source |
| Gain (Loss) on Disposition of Property Plant EquipmentUSD | — | — | -18,000Source | — |
| General and Administrative ExpenseUSD | 4,832,000Source | 5,626,000Source | 5,996,000Source | 6,741,000Source |
| Income Tax Expense (Benefit)USD | — | 45,991,000Source | 59,993,000Source | — |
| Inventory Write-downUSD | 133,000Source | 286,000Source | 866,000Source | 296,000Source |
| Investment Income, InterestUSD | 380,000Source | 738,000Source | 788,000Source | — |
| Net Income (Loss) Attributable to ParentUSD | -11,489,000Source | -16,609,000Source | -7,019,000Source | -16,925,000Source |
| Nonoperating Income (Expense)USD | -6,000Source | 642,000Source | 493,000Source | 172,000Source |
| Payments to Acquire InvestmentsUSD | — | — | — | 20,000,000Source |
| Revenue from Contract with Customer, Including Assessed TaxUSD | 2,371,000Source | 515,000Source | 10,959,000Source | — |
income statement · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Total RevenueUSD | 2,371,000Source | 515,000Source | 10,959,000Source | 299,000Source |
| Cost of Goods and Services Sold | — | — | — | — |
| Operating Income (Loss)USD | -11,483,000Source | -17,251,000Source | -7,512,000Source | -17,097,000Source |
| Income Tax Expense (Benefit)USD | — | 45,991,000Source | 59,993,000Source | — |
| Net Income (Loss) Attributable to ParentUSD | -11,489,000Source | -16,609,000Source | -7,019,000Source | -16,925,000Source |
| Earnings Per Share, BasicUSD per share | -0.94Source | -1.45Source | -0.62Source | -1.53Source |
| Earnings Per Share, DilutedUSD per share | -0.94Source | -1.45Source | -0.62Source | -1.53Source |
| Weighted Average Number of Shares Outstanding, Basicshares | 12,203,269Source | 11,454,180Source | 11,389,168Source | 11,033,310Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | 12,203,269Source | 11,454,180Source | 11,389,168Source | 11,033,310Source |
| Additional Financial Items | ||||
| General and Administrative ExpenseUSD | 4,832,000Source | 5,626,000Source | 5,996,000Source | 6,741,000Source |
| Gross ProfitUSD | 1,536,000Source | -1,110,000Source | 8,968,000Source | -101,000Source |
| Investment Income, InterestUSD | 380,000Source | 738,000Source | 788,000Source | — |
| Investment Income, NetUSD | — | — | — | -172,000Source |
| Nonoperating Income (Expense)USD | -6,000Source | 642,000Source | 493,000Source | 172,000Source |
| Other ExpensesUSD | 11,000Source | 314,000Source | 523Source | — |
| Research and Development ExpenseUSD | 8,187,000Source | 10,515,000Source | 10,484,000Source | 10,255,000Source |
| Revenue from Contract with Customer, Including Assessed TaxUSD | 2,371,000Source | 515,000Source | 10,959,000Source | — |
Offerings
Registration 333-294738
Filing attachments
ea030653601ex99-1.htm · 6-K · 2026-09-24
Exhibit 99.1 LightSolver, a CollPlant Company, and HLRS Joint Research Demonstrated Photonic Computing Can significantly Accelerate Fundamental HPC Workloads Peer-reviewed study published by ACM: LightSolver’s LPU architecture demonstrated significantly lower projected time-to-solution, compared to state-of-the-art algorithms running on a GPU REHOVOT, Israel, September 24, 2026 - CollPlant Biotechnologies Ltd. (Nasdaq: CLGN) today announced the publication of joint research conducted by its s…
Read attachment ↗ea030619401ex99-1.htm · 6-K · 2026-09-22
Exhibit 99.1 CollPlant Regains Compliance with Nasdaq Minimum Bid Price Requirement Nasdaq confirms the Company satisfies continued listing criteria under Listing Rule 5550(a)(2), officially closing the compliance matter Follows the recent completion of the LightSolver acquisition, marking CollPlant’s strategic expansion into high-performance computing (HPC) and photonics REHOVOT, Israel, September 22, 2026 - CollPlant Biotechnologies Ltd. (Nasdaq: CLGN), today announced the receipt of a for…
Read attachment ↗